Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophagectomy | 6 | 2022 | 458 | 0.830 |
Why?
|
Lung Neoplasms | 16 | 2022 | 12183 | 0.640 |
Why?
|
Esophageal Neoplasms | 6 | 2022 | 1449 | 0.640 |
Why?
|
Pneumonectomy | 8 | 2022 | 1066 | 0.630 |
Why?
|
Penetrance | 2 | 2014 | 359 | 0.540 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2022 | 4865 | 0.470 |
Why?
|
Genes, BRCA2 | 2 | 2014 | 590 | 0.460 |
Why?
|
Pleural Neoplasms | 3 | 2022 | 600 | 0.450 |
Why?
|
Genes, BRCA1 | 2 | 2014 | 761 | 0.440 |
Why?
|
Mesothelioma | 3 | 2022 | 774 | 0.420 |
Why?
|
Breast | 2 | 2017 | 1782 | 0.420 |
Why?
|
Neoplasms, Second Primary | 2 | 2014 | 985 | 0.380 |
Why?
|
Heterozygote | 2 | 2014 | 2780 | 0.370 |
Why?
|
Breast Neoplasms | 6 | 2017 | 19800 | 0.310 |
Why?
|
Models, Genetic | 2 | 2014 | 3539 | 0.300 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2021 | 697 | 0.290 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 902 | 0.280 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2561 | 0.270 |
Why?
|
Empyema | 1 | 2021 | 40 | 0.220 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 50 | 0.220 |
Why?
|
Interneurons | 2 | 2016 | 577 | 0.210 |
Why?
|
Carcinoma, Large Cell | 1 | 2021 | 111 | 0.210 |
Why?
|
Neoplasm Staging | 12 | 2022 | 11126 | 0.210 |
Why?
|
Precancerous Conditions | 3 | 2017 | 964 | 0.210 |
Why?
|
Music Therapy | 1 | 2021 | 92 | 0.200 |
Why?
|
Lymphatic Metastasis | 4 | 2021 | 2951 | 0.200 |
Why?
|
Thoracic Neoplasms | 1 | 2022 | 259 | 0.200 |
Why?
|
Keratins | 1 | 2021 | 534 | 0.190 |
Why?
|
Gastrostomy | 1 | 2022 | 299 | 0.190 |
Why?
|
Pneumothorax | 1 | 2022 | 392 | 0.180 |
Why?
|
Hyperplasia | 3 | 2017 | 1182 | 0.180 |
Why?
|
Retrospective Studies | 22 | 2022 | 71483 | 0.170 |
Why?
|
Hospices | 1 | 2020 | 237 | 0.160 |
Why?
|
Gastrectomy | 1 | 2021 | 538 | 0.160 |
Why?
|
Chlamydia trachomatis | 1 | 2019 | 244 | 0.160 |
Why?
|
Ependymoma | 1 | 2020 | 324 | 0.160 |
Why?
|
raf Kinases | 1 | 2017 | 121 | 0.160 |
Why?
|
Learning Curve | 1 | 2018 | 202 | 0.160 |
Why?
|
Contact Tracing | 1 | 2019 | 258 | 0.150 |
Why?
|
Hydrocarbons | 1 | 2016 | 79 | 0.150 |
Why?
|
Organ Culture Techniques | 2 | 2015 | 861 | 0.150 |
Why?
|
Preoptic Area | 1 | 2016 | 153 | 0.140 |
Why?
|
Thoracic Surgery | 1 | 2022 | 684 | 0.140 |
Why?
|
Chlamydia Infections | 1 | 2019 | 351 | 0.140 |
Why?
|
Astrocytoma | 2 | 2017 | 794 | 0.140 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2017 | 219 | 0.140 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 725 | 0.140 |
Why?
|
Telencephalon | 1 | 2015 | 145 | 0.140 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1146 | 0.130 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2021 | 682 | 0.130 |
Why?
|
Hospice Care | 1 | 2020 | 609 | 0.120 |
Why?
|
Carcinoma, Lobular | 2 | 2015 | 482 | 0.120 |
Why?
|
Aged | 20 | 2022 | 161488 | 0.120 |
Why?
|
Adenocarcinoma | 2 | 2021 | 6338 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 548 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6765 | 0.120 |
Why?
|
Humans | 46 | 2022 | 708843 | 0.120 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2021 | 991 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 1 | 2021 | 1155 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 8877 | 0.110 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 865 | 0.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11253 | 0.110 |
Why?
|
Protein Multimerization | 1 | 2017 | 1001 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 952 | 0.110 |
Why?
|
Calibration | 1 | 2014 | 802 | 0.110 |
Why?
|
Prognosis | 8 | 2021 | 28919 | 0.110 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2040 | 0.110 |
Why?
|
Coculture Techniques | 1 | 2015 | 1374 | 0.110 |
Why?
|
Neural Inhibition | 1 | 2015 | 592 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2012 | 206 | 0.110 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2459 | 0.100 |
Why?
|
Survival Rate | 6 | 2021 | 13202 | 0.100 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 254 | 0.100 |
Why?
|
Smoking Cessation | 1 | 2022 | 2032 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 1086 | 0.100 |
Why?
|
Sarcoma | 1 | 2021 | 1854 | 0.100 |
Why?
|
Chemoprevention | 1 | 2012 | 313 | 0.100 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 475 | 0.100 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2029 | 0.100 |
Why?
|
Critical Illness | 1 | 2022 | 2496 | 0.090 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2015 | 3281 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2159 | 0.090 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 821 | 0.090 |
Why?
|
Postoperative Complications | 5 | 2022 | 15053 | 0.090 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1597 | 0.090 |
Why?
|
HIV Antibodies | 1 | 2015 | 1258 | 0.090 |
Why?
|
Lung | 3 | 2022 | 9706 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13714 | 0.080 |
Why?
|
Neural Stem Cells | 1 | 2015 | 900 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1047 | 0.080 |
Why?
|
Middle Aged | 15 | 2022 | 213752 | 0.080 |
Why?
|
Palliative Care | 1 | 2022 | 3261 | 0.080 |
Why?
|
Female | 20 | 2022 | 375205 | 0.080 |
Why?
|
SEER Program | 1 | 2012 | 1549 | 0.080 |
Why?
|
Treatment Outcome | 10 | 2022 | 61932 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 1600 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2017 | 1922 | 0.080 |
Why?
|
Frail Elderly | 2 | 2022 | 599 | 0.080 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3308 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2015 | 2987 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4724 | 0.070 |
Why?
|
Mass Screening | 2 | 2019 | 5182 | 0.070 |
Why?
|
Antibodies, Neutralizing | 1 | 2015 | 1796 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 3876 | 0.070 |
Why?
|
Adult | 13 | 2021 | 211041 | 0.070 |
Why?
|
Fibroblasts | 1 | 2016 | 4299 | 0.070 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1264 | 0.070 |
Why?
|
Bayes Theorem | 1 | 2012 | 1994 | 0.070 |
Why?
|
Brain Neoplasms | 2 | 2017 | 8776 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2022 | 58184 | 0.070 |
Why?
|
Peptides | 1 | 2016 | 4424 | 0.060 |
Why?
|
Geriatric Assessment | 2 | 2022 | 1309 | 0.060 |
Why?
|
Age Factors | 2 | 2021 | 18712 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2017 | 17218 | 0.060 |
Why?
|
Young Adult | 7 | 2021 | 55940 | 0.060 |
Why?
|
Nerve Net | 1 | 2015 | 2138 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2709 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2015 | 2768 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5489 | 0.060 |
Why?
|
Clinical Competence | 1 | 2018 | 4615 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3515 | 0.060 |
Why?
|
Male | 16 | 2022 | 349524 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 23284 | 0.060 |
Why?
|
Hypesthesia | 1 | 2021 | 102 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2021 | 4883 | 0.050 |
Why?
|
Transcription Factors | 1 | 2021 | 12005 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6571 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5405 | 0.050 |
Why?
|
Risk Factors | 7 | 2022 | 69553 | 0.050 |
Why?
|
Risk | 1 | 2012 | 9641 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39038 | 0.050 |
Why?
|
HIV Infections | 2 | 2016 | 15538 | 0.050 |
Why?
|
Hospitalization | 1 | 2019 | 9644 | 0.050 |
Why?
|
Indocyanine Green | 1 | 2020 | 211 | 0.050 |
Why?
|
Physician Assistants | 1 | 2021 | 163 | 0.050 |
Why?
|
Polypharmacy | 1 | 2021 | 270 | 0.050 |
Why?
|
Lymph Nodes | 2 | 2021 | 3409 | 0.050 |
Why?
|
Remission Induction | 2 | 2015 | 2399 | 0.050 |
Why?
|
Mutation | 2 | 2014 | 29262 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 550 | 0.040 |
Why?
|
Tracheostomy | 1 | 2022 | 400 | 0.040 |
Why?
|
Infant, Low Birth Weight | 1 | 2022 | 833 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 797 | 0.040 |
Why?
|
Anastomotic Leak | 1 | 2018 | 126 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2021 | 275 | 0.040 |
Why?
|
HIV-1 | 1 | 2015 | 6757 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9754 | 0.040 |
Why?
|
Time Factors | 4 | 2021 | 41038 | 0.040 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2022 | 720 | 0.040 |
Why?
|
Caribbean Region | 1 | 2016 | 175 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12292 | 0.040 |
Why?
|
Naphthalimides | 1 | 2015 | 21 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 996 | 0.040 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 26 | 0.040 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 2865 | 0.030 |
Why?
|
Neoplasms | 2 | 2021 | 20172 | 0.030 |
Why?
|
Daunorubicin | 1 | 2015 | 152 | 0.030 |
Why?
|
United States | 5 | 2022 | 67165 | 0.030 |
Why?
|
Sexual Partners | 1 | 2019 | 690 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2020 | 1179 | 0.030 |
Why?
|
Automation, Laboratory | 1 | 2014 | 98 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1450 | 0.030 |
Why?
|
Prosencephalon | 1 | 2016 | 317 | 0.030 |
Why?
|
Mexico | 1 | 2016 | 673 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2927 | 0.030 |
Why?
|
Survival Analysis | 2 | 2020 | 10507 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 206 | 0.030 |
Why?
|
Dyspnea | 1 | 2021 | 1237 | 0.030 |
Why?
|
Intention | 1 | 2016 | 312 | 0.030 |
Why?
|
Paclitaxel | 1 | 2021 | 1655 | 0.030 |
Why?
|
Cytarabine | 1 | 2015 | 689 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 580 | 0.030 |
Why?
|
Microspheres | 1 | 2015 | 801 | 0.030 |
Why?
|
Child | 4 | 2022 | 73636 | 0.030 |
Why?
|
Vincristine | 1 | 2014 | 1039 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1539 | 0.030 |
Why?
|
Adolescent | 4 | 2021 | 84718 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 385 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 970 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 726 | 0.030 |
Why?
|
Sexually Transmitted Diseases | 1 | 2016 | 558 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 927 | 0.030 |
Why?
|
Androstadienes | 1 | 2012 | 345 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 2017 | 992 | 0.030 |
Why?
|
Self Report | 1 | 2021 | 3397 | 0.030 |
Why?
|
Quality of Life | 2 | 2021 | 11594 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2758 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2315 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1556 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2303 | 0.020 |
Why?
|
Adenine | 1 | 2015 | 916 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 2980 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 7026 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1399 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 2193 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2750 | 0.020 |
Why?
|
Prospective Studies | 3 | 2021 | 50597 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2015 | 1759 | 0.020 |
Why?
|
Mice | 4 | 2017 | 80876 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1730 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2189 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 7994 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3714 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4159 | 0.020 |
Why?
|
Boston | 1 | 2022 | 9402 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3690 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8896 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2235 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 2836 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 7644 | 0.020 |
Why?
|
Tamoxifen | 1 | 2012 | 989 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 13647 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2015 | 1977 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 3887 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6257 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 8992 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8712 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3693 | 0.020 |
Why?
|
Pain | 1 | 2021 | 4636 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 5045 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2021 | 4176 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8024 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2630 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9488 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4317 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 8612 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2014 | 2550 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2021 | 13536 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2020 | 4266 | 0.020 |
Why?
|
Patient Readmission | 1 | 2018 | 2952 | 0.020 |
Why?
|
Genomics | 1 | 2020 | 5300 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8638 | 0.020 |
Why?
|
Mammography | 1 | 2015 | 2442 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10803 | 0.020 |
Why?
|
Animals | 4 | 2017 | 170486 | 0.020 |
Why?
|
Physicians | 1 | 2021 | 4292 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 3075 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7487 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 5691 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4165 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 3507 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 16008 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11718 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 24433 | 0.010 |
Why?
|
Models, Statistical | 1 | 2017 | 5034 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 14712 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2015 | 4592 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4677 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 8014 | 0.010 |
Why?
|
Neurons | 1 | 2020 | 9385 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12447 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11790 | 0.010 |
Why?
|
Infant | 1 | 2022 | 34261 | 0.010 |
Why?
|
Depression | 1 | 2019 | 7202 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6395 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5982 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20308 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 20170 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2015 | 5703 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9556 | 0.010 |
Why?
|